An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development
- PMID: 34323636
- DOI: 10.1080/14656566.2021.1951224
An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development
Abstract
Introduction: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease that may affect 3 in 1,000 people within the general population. The therapeutic scenario is complex, and no therapy has proved to be able to modify the natural course of the disease, nor to prevent the most severe systemic complications.Areas covered: Recently, the EULAR 2020 Recommendations for pSS have underlined the low level of evidence supporting efficacious therapeutic approaches, lacking a definition of specific treatment targets and being far from the 'disease modification' concept that is frequently used in other diseases. Herein, the authors review the status of current targeted therapies and provide the reader with their expert opinion.Expert opinion: The progress in discovering novel treatments for pSS seem to be focused on searching new biological therapies as highly-selective drugs that can be effective without the adverse effects related to the wide, nonspecific immunosuppression induced by the drugs currently used. Most likely, the more disruptive therapeutic approach in pSS that could be seen in a few years is the use of combination strategies targeting different etiopathogenic pathways.
Keywords: Primary sjögren syndrome; abatacept; anakinra; b cell activating factor receptor-blocking; baminercept; phosphatidylinositol 3-kinase delta inhibitor; rituximab; targets cd40; tocilizumab.
Similar articles
-
Emerging drugs for primary Sjögren's syndrome.Expert Opin Emerg Drugs. 2019 Jun;24(2):121-132. doi: 10.1080/14728214.2019.1634052. Expert Opin Emerg Drugs. 2019. PMID: 31286787 Review.
-
Use of Biologics in Sjögren's Syndrome.Rheum Dis Clin North Am. 2016 Aug;42(3):407-17. doi: 10.1016/j.rdc.2016.03.001. Epub 2016 Jun 21. Rheum Dis Clin North Am. 2016. PMID: 27431344 Review.
-
Current and future therapies for primary Sjögren syndrome.Nat Rev Rheumatol. 2021 Aug;17(8):475-486. doi: 10.1038/s41584-021-00634-x. Epub 2021 Jun 29. Nat Rev Rheumatol. 2021. PMID: 34188206 Review.
-
Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.Drugs. 2016 Nov;76(17):1601-1623. doi: 10.1007/s40265-016-0659-z. Drugs. 2016. PMID: 27844414 Review.
-
SER recommendations on the use of biological drugs in primary Sjögren's syndrome.Reumatol Clin (Engl Ed). 2019 Nov-Dec;15(6):315-326. doi: 10.1016/j.reuma.2018.10.014. Epub 2019 Jan 23. Reumatol Clin (Engl Ed). 2019. PMID: 30683506 English, Spanish.
Cited by
-
The Spectrum of Extraglandular Manifestations in Primary Sjögren's Syndrome.J Pers Med. 2023 Jun 7;13(6):961. doi: 10.3390/jpm13060961. J Pers Med. 2023. PMID: 37373950 Free PMC article. Review.
-
Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies.Nat Rev Rheumatol. 2023 May;19(5):288-306. doi: 10.1038/s41584-023-00932-6. Epub 2023 Mar 13. Nat Rev Rheumatol. 2023. PMID: 36914790 Free PMC article. Review.
-
A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren's Syndrome.Front Immunol. 2022 Jul 28;13:924730. doi: 10.3389/fimmu.2022.924730. eCollection 2022. Front Immunol. 2022. PMID: 35967307 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials